- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Sylentis to Start Clinical Trial of SYL040012 for the Treatment of Ocular Hypertension

Posted By Dr. Dominique Walton Brooks On August 27, 2009 @ 5:58 am In Glaucoma,Industry News,Optic Nerve | Comments Disabled

Sylentis has announced that the organization expects to dose the first patients in the phase I study of its glaucoma-associated ocular hypertension drug SYL040012 in Spain around the end of September. Sylentis received approval last month from the Spanish regulatory agency to begin trials.

This Phase I study will take place at the Unit for Phase I Clinical Assays at the Clínica Universitaria de Navarra on healthy volunteers. The goal of this trial is to ensure the safety of the agent.

SYL040012 is a siRNA which is specific for the adrenergic receptor beta-2. This experimental agent has shown in vivo efficacy reducing intraocular pressure as well as a prophylactic effect on glaucoma prevention in animal models according to the company’s website.

Read the article [1] and the press release for approval of the trial [2].


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/002023-sylentis-to-start-clinical-trial-of-syl040012-for-the-treatment-of-ocular-hypertension/

URLs in this post:

[1] article: http://www.genomeweb.com/rnai/sylentis-aims-begin-phase-i-study-glaucoma-drug-september

[2] trial: http://www.sylentis.com/index.php?option=com_content&view=article&id=28%3Asylentis-recibe-autorizacion-para-comenzar-ensayos-de-fase-i-con-syl040012-para-la-hipertension-ocular-asociada-a-glaucoma&catid=4%3Anoticias-sylentis&Itemid=31&lang=en

Copyright © 2008 Eye Doc Talk. All rights reserved.